SHL – UBS rates the stock as Sell

By Broker News | More Articles by Broker News

Sonic Healthcare’s earnings fell slightly short of UBS estimates despite a beat on revenue thanks to a solid contribution from Aurora.

A strong performance from Australia and UK pathology and imaging was not enough to offset margin weakness in the US.

As the stock is trading on a 24.7x forward PE versus an average 21.3x the broker retains Sell. Target unchanged at $26.50.

Sector: Health Care Equipment & Services.

Target price is $26.50.Current Price is $31.58. Difference: ($5.08) – (brackets indicate current price is over target). If SHL meets the UBS target it will return approximately -19% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →